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Summary: In pregnant women assessed for parasitemia every 28 days, the risk of placental 
malaria increased in a dose-response relationship with both increasing frequency and density of 
parasitemia; however, even women with only submicroscopic parasitemia were at risk for 
placental malaria. 
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Abstract 
Background: Placental malaria is a major cause of adverse birth outcomes. However, data are 
limited on the relationships between longitudinal measures of parasitemia during pregnancy and 
placental malaria.  
Methods: Data come from 637 women enrolled in a randomized controlled trial of intermittent 
preventive treatment of malaria in pregnancy (IPTp) from Uganda. Plasmodium falciparum 
parasitemia was assessed using microscopy and ultrasensitive quantitative PCR at intervals of 28 
days from 12-20 weeks gestation through delivery. Multivariate analysis was used to measure 
associations between characteristics of parasitemia during pregnancy and the risk of placental 
malaria based on histopathology.  
Results: Overall risk of placental malaria was 44.6%. None of the 34 women without 
parasitemia detected during pregnancy had evidence of placental malaria. Increasing proportion 
of interval assessments with parasitemia and higher parasite densities were independently 
associated with an increased risk of placental malaria. Higher gravidity and more effective IPTp 
were associated with a decreased risk of placental malaria. Women with parasitemia only 
detected before the 3
rd
 trimester still had an increased risk of placental malaria.   
Conclusions:  The frequency, density, and timing of parasitemia are all important risk factors for 
placental malaria. Interventions should target the prevention of all levels of parasitemia 
throughout pregnancy.  
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INTRODUCTION 
 In Africa, approximately 30 million pregnant women are at risk of Plasmodium 
falciparum infection every year (1). In this setting, a high proportion of infected women are 
asymptomatic, with low level parasitemia that can nonetheless lead to placental sequestration. 
Placental malaria is common, with 25 to 40% of women in sub-Saharan Africa having evidence 
of placental malaria at time of delivery, and is associated with poor birth outcomes (2,3). Babies 
born to mothers with placental malaria have twice the risk of low birth weight (LBW) (4) and 
stillbirth (5) compared to those born to mothers without placental malaria.  Malaria in pregnancy 
is estimated to cause 900,000 LBW deliveries and 100,000 infant deaths each year (6,7). In high-
transmission areas, primigravidae are at greater risk of infection, and slowly acquire immunity to 
placental malaria through consecutive pregnancies (2).  Because of both parity-specific and age-
related immunity, P. falciparum infection can be difficult to diagnose during pregnancy, as 
peripheral infections are often submicroscopic and asymptomatic, especially in multigravida 
women (8,9).  Because of this, the World Health Organization (WHO) recommends the use of 
intermittent preventative treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), 
which is intended to clear current infections and provide a period of prophylaxis to prevent 
future infections (2).  
While associations between microscopic parasitemia during pregnancy and placental 
malaria have been reported in several studies, the impact of submicroscopic infection has been 
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less well studied (2,9). Advances in molecular diagnostics, including the development of 
ultrasensitive nucleic-acid based assays such as the var gene acidic terminal sequence (varATS) 
quantitative PCR (qPCR), now allow for detection of parasite densities as low as 0.06-0.15 
parasites per microliter (p/uL) (10).  Most prior studies of parasitemia during pregnancy have 
been cross-sectional, and those that were longitudinal did not utilize ultrasensitive techniques or 
had limited interval assessments for parasitemia (11–13), meaning that some infections, 
particularly low-density ones, were likely to have been missed.  Frequent assessments for 
parasitemia using ultrasensitive qPCR should allow for a more accurate estimation of the burden 
of parasitemia during pregnancy and improve our ability to investigate the impact of 
submicroscopic parasitemia on the development of placental malaria.  
Recently, given widespread resistance to SP, there has been concern for diminishing 
efficacy of IPTp (14,15). Several studies have focused on the arteminisin-based combination 
therapy (ACT) dihydroartemisinin-piperaquine (DP) as an alternative to SP. Three recent studies 
from East Africa showed that IPTp with DP was more effective than SP at reducing the risk of 
malaria during pregnancy and the risk of placental malaria at delivery (16–18). In this study, we 
utilized ultrasensitive qPCR data obtained every 28 days from pregnant women enrolled in a 
randomized controlled trial comparing monthly IPTp with SP versus DP in Uganda to conduct a 
detailed longitudinal study of the impact of P. falciparum infection during pregnancy. A better 
understanding of how the frequency, density and timing of parasitemia during pregnancy affects 
the risk of placental malaria is crucial for developing effective strategies to prevent malaria in 
pregnancy.   
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METHODS 
Study Setting and Participants 
Data come from a previously published double-blind, randomized controlled trial 
comparing monthly SP and monthly DP for IPTp conducted from September 2016 to December 
2017 in Busia District, an area in southeastern Uganda where malaria transmission is perennial 
and intense (18). In Busia District, the only vector control interventions conducted prior to or 
during this trial were two district-wide long-acting insecticide treated net (LLIN) distribution 
campaigns in May 2013 and April 2017. Briefly, eligible participants were HIV-uninfected 
women at least 16 years of age with a viable pregnancy between 12 and 20 weeks gestation 
confirmed by ultrasound. IPTp was administered every 4 weeks starting at 16 or 20 weeks 
gestational age. For the present study, all women with a singleton delivery at > 28 weeks 
gestational age with placental histopathology results were included (Figure 1).  
Study procedures 
Routine visits were conducted every 4 weeks, including collection of blood for the 
detection of malaria parasites by microscopy and qPCR. Women were not treated for a positive 
blood smear at a routine visit unless they were febrile, in accordance with the standard of care in 
Uganda. Women were encouraged to come to the clinic when ill. Those who presented with a 
tympanic temperature > 38.0˚C or history of fever in the previous 24 hours had blood collected 
for a thick blood smear. If the smear was positive, the patient was diagnosed with malaria and 
treated with artemether-lumefantrine. qPCR was not performed at unscheduled sick visits in 
accordance with study protocol. Placental tissue, placental blood, and maternal blood were 
collected at the time of delivery.  
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Laboratory procedures 
Blood smears were stained with 2% Giemsa and read by experienced microscopists.  A 
blood smear was considered negative when the examination of 100 high power fields did not 
reveal asexual parasites. All slides were read by a second microscopist and a third reviewer 
settled any discrepant readings. We collected 200 microliters of blood at enrollment and at the 
time of each routine visit to test for the presence of parasitemia using an ultrasensitive qPCR 
assay targeting the multicopy conserved var gene acidic terminal sequence (10). Placental blood 
was tested for the presence of malaria parasites by microscopy and loop-mediated isothermal 
amplification (LAMP) kit (Eiken Chemical, Japan) as previously described (19). Placental tissue 
was evaluated for histopathological evidence of active or past infection with malaria parasites 
based on the detection of malaria parasites and/or hemozoin pigment in intervillous fibrin and 
macrophages, using standardized criteria as previously described (20).  
 
Variables of interest 
The primary outcome was the prevalence of placental malaria, defined as the presence of 
any parasites or hemozoin pigment detected by histopathology. To evaluate the magnitude of 
placental malaria, we also assessed the proportion of high-powered fields in which any hemozoin 
pigment was detected as a secondary outcome. Symptomatic malaria was defined as fever with a 
positive blood smear. Interval assessments for parasitemia were performed at the enrollment 
visit, at routine visits that occurred approximately every 4 weeks through delivery, and at 
unscheduled visits in febrile patients. For each enrollment and routine visit, we assessed for the 
presence or absence of 1) microscopic parasitemia and 2) any parasitemia (by microscopy or 
qPCR); at unscheduled visits, only microscopic parasitemia was assessed. The frequency of 
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detection of parasitemia was summarized as the proportion of interval assessments with 
parasitemia (number of interval assessments with microscopic or any parasitemia divided by the 
total number of interval assessments). Proportion of interval assessments with parasitemia was 
then categorized into five strata: 0%, 0-25%, >25-50%, >50-75%, and >75-100%, to best 
demonstrate relationships with outcomes of interest. Geometric mean parasite density for each 
participant was calculated by adding 1 to each qPCR parasite density, taking the geometric mean 
of all parasite densities (microscopic and qPCR), and then subtracting 1. Geometric mean 
parasite density was then categorized into three strata: <1 p/uL, 1-10 p/uL,, and >10 p/uL as this 
best reflected relationships with the outcome of interest.  When parasite densities were available 
by both microscopy and qPCR, the qPCR value was used.  
 
Statistical analysis 
Statistical analyses were performed using Stata software, version 14 (StataCorp) and 
Rstudio, version 1.0.143. Comparisons of simple proportions were made using the chi-square test 
or Fisher’s exact test. One-way analysis of variance (ANOVA) was used for normally-distributed 
continuous variables. Associations between the proportion of interval assessments with 
parasitemia and density of parasitemia during pregnancy with the risk of placental malaria were 
made using univariate and multivariate generalized linear Poisson regression models with robust 
standard errors. All models were adjusted for gravidity and IPTp regimen. We assumed a two-
sided significance level of 0.05.   
 
Results 
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Among 782 women enrolled, 95 (12.1%) were excluded before delivery and 50 (6.4%) 
after delivery resulting in 637 women included in the analyses (Figure 1). At enrollment, mean 
maternal age, mean gestational age, and gravidity were similar between the two IPTp arms 
(Table 1). LLIN use was similar between the two groups with women in the SP arm reporting 
sleeping under a LLIN the previous night on 84.4% of clinic visits versus 85.7% in the DP arm. 
Participants underwent a median of 8 interval assessments (range 4-9) for parasitemia during 
pregnancy. There were no significant differences in the incidence of malaria (incidence rate ratio 
= 0.71, 95% CI 0.33-1.55, p=0.39) or measures of parasitemia before initiation of IPTp between 
the two treatment arms. After initiation of IPTp, women randomized to DP experienced a lower 
incidence of malaria (0.02 versus 0.54 episodes ppy, p-value <0.001), and fewer interval 
assessments with microscopic parasitemia (0.5% versus 30.6%, p<0.001) or any parasitemia 
(20.2% versus 64.2%, p<0.001). IPTp with DP was also associated with a significantly lower 
prevalence of parasites detected in placental blood by microscopy (0.3% versus 8.8%, p<0.001) 
or LAMP (2.2% versus 22.3%, p<0.001), and any evidence of placenta malaria by 
histopathology (28.2% vs. 61.7%, p<0.001). Notably, among those with any evidence of 
placental malaria by histopathology, parasites were detected in only 9.5%; therefore, we chose to 
use the presence of any parasites or pigment as the outcome for placental malaria by 
histopathology. Because histopathology provided the most sensitive measure of placental 
malaria, as has been shown in other studies (21), this was chosen as the primary outcome for the 
remainder of the analyses.  
Associations between proportion of interval assessments with parasitemia and placental 
malaria  
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There was a strong “dose response” relationship between the proportion of interval 
assessments with microscopic or any parasitemia and the risk of placental malaria (p<0.001 
using chi squared test for trend for both comparisons) (Figure 2).  Among 34 women in which 
parasitemia was never detected by microscopy or qPCR during pregnancy, none had evidence of 
placental malaria. Notably, there were 16 mothers who developed placental malaria in whom 
only submicroscopic parasitemia was detected. In contrast, among 111 women with parasitemia 
detected in over 75% of interval assessments, the risk of placental malaria was 87.4%. When 
limiting the analysis to only parasitemia detected by microscopy, among 81 women with 
parasitemia detected in over 50% of interval assessments, all but 1 (98.8%) had evidence of 
placental malaria. Primigravida women were more likely to develop placental malaria than 
multigravidae, but the “dose response” relationship between the proportion of interval 
assessments with microscopic or any parasitemia and the risk of placental malaria held within 
each category of gravidity (Supplemental Figure 1).  Additionally, among the 284 women with 
placental malaria, an increasing proportion of interval assessments with any parasitemia was also 
associated with increasing proportion of high-powered fields with hemozoin pigment 
(p<0.001)(Figure 3). Thus, increasing frequency of detection of parasitemia during pregnancy 
was associated not only with an increased risk of placental malaria, but also with an increased 
amount of affected tissue in the placenta.  
Associations between geometric mean parasite density and placental malaria 
In addition to the presence or absence of parasitemia, we assessed whether the degree of 
parasitemia, as measured by the geometric mean parasite density, was associated with placental 
malaria. We found that there was a strong “dose response” relationship between higher 
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geometric mean parasite density and an increased risk of placental malaria; this relationship was 
preserved within each category of gravidity (Supplemental Figure 2). When stratified by 
proportion of interval assessments with any parasitemia, higher geometric mean parasite 
densities remained associated with a higher risk of placental malaria (p<0.001)(Figure 4); among 
110 women with any parasitemia detected in over 50% of interval assessments and a geometric 
mean parasite density of > 10 p/uL, the risk of placental malaria was 94.5%. Notably, the risk for 
placental malaria remained >50% in women with lower geometric mean parasite densities 
(between 1-10 p/uL) if they had greater than 50% of interval assessments with parasitemia.  In 
the 182 women who never had a parasite density of > 100 p/uL on any visit, i.e. likely missed by 
standard diagnostic tests, higher geometric mean parasite density was still associated with 
increased risk of placental malaria; in this group, only 6% of those with a geometric mean 
parasite density of <= 1 p/uL developed placental malaria, while 13.9% of those who had a 
geometric mean parasite density of > 1 p/uL developed placental malaria (p = 0.07).  
Adjusted model suggests independent associations of measures of parasitemia, IPTp, and 
gravidity with placental malaria 
In univariate analysis, an increase in the frequency and density of parasitemia were 
strongly associated with an increasing risk of placental malaria, as discussed above and presented 
in Table 2. Increasing gravidity and IPTp with DP were associated with a decreased risk of 
placental malaria, relationships that have been previously reported. Interestingly, in adjusted 
analysis, although all measures of associations decreased in magnitude (suggesting some degree 
of confounding), all of the risk factors assessed remained independently associated with 
placental malaria. These data provide further evidence that the frequency and density of 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz130/5395973 by London School of H
ygiene & Tropical M
edicine user on 15 April 2019
Ac
ce
pte
d M
an
us
cri
pt
 
Page 12 of 32 
 
parasitemia during pregnancy, although correlated, contribute independently towards the risk of 
developing placental malaria.  Increasing gravidity and IPTp with DP also remained significantly 
associated with a lower risk of placental malaria in multivariate analysis, suggesting that 
immunity and antimalarial drugs may modulate the risk of developing placental malaria 
independent of the frequency and density of parasitemia in the peripheral blood.  
Timing of parasitemia  
To explore the effect of the timing of parasitemia during gestation on the risk of placental 
malaria, we stratified the women into categories of those who never had parasitemia detected  
(n =34), those with any parasitemia detected only prior to the 3
rd
 trimester (n=204), those with 
any parasitemia detected only during the 3
rd
 trimester (n=21), and those with any parasitemia 
both before and during the 3
rd
 trimester (n=378). Compared to women with no parasitemia 
detected (none of whom developed placental malaria), the risk of placental malaria was similarly 
higher among those with parasitemia detected only prior to the 3
rd
 trimester (30.4%, p<0.001) or 
only during the 3
rd
 trimester (23.8%, p=0.003) and highest in those with parasitemia both before 
and during the 3
rd
 trimester (57.4%, p<0.001)(Table 3). A similar pattern was seen when limited 
to women who received IPTp with SP. In contrast, among women who received IPTp with DP, 
none of the 10 women with parasitemia detected only in the 3
rd
 trimester developed placental 
malaria, while the risk of placental malaria was similar among those with parasitemia only 
detected prior to the 3
rd
 trimester (31.1%) and those with parasitemia detected before and during 
the 3
rd
 trimester (32.5%).  These data suggest that regardless of the IPTp regimen, parasitemia 
limited to before the 3
rd
 trimester is still associated with an increased risk of placental malaria. 
DISCUSSION  
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 We investigated associations between the frequency, density, and timing of parasitemia 
during pregnancy with the development of placental malaria in an intensely followed cohort of 
Ugandan women enrolled in a clinical trial of IPTp. The key novel aspects of this study were the 
frequent use of a highly sensitive qPCR assay in addition to traditional microscopy for the 
assessment of parasitemia during pregnancy and the use of histopathology to assess for placental 
malaria. When assessing for parasitemia every 4 weeks starting at 12-20 weeks of gestational 
age, there was a strong positive relationship between the proportion of interval assessments 
positive for parasitemia and the risk of placental malaria. Higher parasite densities were also 
independently associated with an increased risk of placental malaria; however, even women with 
only submicroscopic parasitemia were at risk for placental malaria. Notably, among women with 
no parasitemia detected during the study, none had evidence of placental malaria. Finally, 
regardless of the IPTp regimen, parasitemia limited to the period before the 3
rd
 trimester was still 
associated with an increased risk of placental malaria. DP did not appear to clear early infections 
already established in the placenta but was highly effective in preventing placental malaria when 
infections occurred only later in the course of pregnancy.  
 Most studies of parasitemia during pregnancy have been cross-sectional, with parasitemia 
only assessed at enrollment or delivery. One longitudinal study in Uganda screened mothers 
weekly with RDTs and found that multiple episodes of parasitemia and higher levels of 
parasitemia were both associated with adverse birth outcomes; however, this study did not assess 
mothers for submicroscopic parasitemia and placental histopathology was only available in a 
subset (22).  A study in Malawi found a dose-response relationship between the number of 
malaria infections diagnosed by microscopy and risk of LBW but also did not measure 
submicroscopic parasitemia or placental outcomes (23). A longitudinal study that used a less 
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sensitive PCR assay to detect submicroscopic parasitemia found that after controlling for 
microscopic parasitemia, each additional episode of submicroscopic parasitemia increased the 
risk of placental malaria (13). Our study confirms the finding that increasing frequency of 
detection of any parasitemia during pregnancy increases the risk of placental malaria.  
The longitudinal study above using a less sensitive PCR assay also demonstrated that 
women with only submicroscopic infections were more likely to have placental malaria than 
women without any documented infection during pregnancy (13). Notably, in that study, 35% of 
women with evidence of placental malaria did not have any peripheral infections detected during 
pregnancy or at delivery (13). However, in our cohort, women without documented parasitemia 
during pregnancy did not develop placental malaria.  This implies that either the early gestational 
age at which most participants were enrolled, the frequency of screening, the use of ultrasensitive 
qPCR, or the combination of all three allowed us to more accurately assess the true burden of 
parasitemia in these women. Furthermore, it provides reassurance that ultrasensitive qPCR is 
sensitive enough to detect any level of parasitemia that might lead to sequestration of parasites in 
the placenta.  
An alternative approach to IPTp is intermittent screening and treatment (ISTp), in which 
women are screened for parasitemia intermittently during pregnancy and only given antimalarial 
therapy if they test positive for malaria parasites. Two recent trials, using rapid diagnostic tests 
(RDTs) to assess women at regular intervals for parasitemia, evaluated ISTp with DP versus 
standard-of-care IPTp with SP. Both studies showed that ISTp with DP was inferior for 
preventing placental malaria compared to IPTp with SP (16,24). This was likely because the 
rapid diagnostic tests (RDTs) used for screening were not sensitive enough to detect low-density 
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parasitemia, which can lead to placental malaria. Given the high burden of submicroscopic 
infections, and the fact that even women with only submicroscopic parasitemia had an increased 
risk of placental malaria, our study provides additional evidence that an ISTp strategy to prevent 
placental malaria has serious limitations given the level of sensitivity of currently available 
point-of-care diagnostic tests.  
Prospective studies assessing the relationship between the timing of parasitemia during 
pregnancy and the risk of placental malaria have reached conflicting conclusions (25-31), and 
most have not included assessments for submicroscopic parasitemia or placental histopathology. 
Our data provide direct evidence that infections before the third trimester increase the risk for 
placental malaria even in those without any microscopic or submicroscopic parasitemia in the 
third trimester and provides support for the WHO recommendation to start dosing IPTp in the 
second trimester and to give at least 3 doses during pregnancy, no matter which antimalarial 
regimen is chosen. 
 This study had several limitations. Of the women enrolled in the primary trial, 18.5% 
were excluded from this analysis. The primary reason for exclusion was missing histopathology 
data. Reassuringly, neither gravidity nor prevalence of microscopic or submicroscopic 
parasitemia at enrollment varied significantly between those who were excluded and included. 
Furthermore, episodes of parasitemia were not genotyped; therefore, we cannot say whether 
repeated infections in women were new or persistent. However, because women were assessed 
every 28 days, we do have an accurate measurement of the proportion of time during pregnancy 
that they were actively infected. Another limitation of this analysis is that we did not investigate 
associations between parasitemia during pregnancy and birth outcomes.  While one study in 
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Benin showed an association between submicroscopic parasitemia and poor birth outcomes, two 
other studies have not (12, 13, 32). Given that adverse birth outcomes are multifactorial and 
relatively uncommon events, we feel that this question is best addressed in a planned separate 
analysis. Additionally, because we enrolled women near the end of the first trimester and during 
the early 2
nd
 trimester, we cannot comment on the impact of parasitemia during the first trimester 
on the development of placental malaria. Finally, this study was conducted in a region with 
perennially high malaria transmission and the results may not be generalizable to areas that have 
a more seasonal transmission pattern or lower transmission intensity.  
 In conclusion, our data suggest that in a region with high malaria transmission intensity, 
the risk of placental malaria increases in a dose-response relationship with both increasing 
frequency and density of parasitemia.  Importantly, however, even women with only 
submicroscopic infection have an increased risk of placental malaria compared to women 
without any parasitemia. Women with parasitemia limited to the period before the 3
rd
 trimester 
remain at risk for placental malaria. These results provide additional evidence for an IPTp 
strategy over ISTp to prevent placental malaria in women living in malaria endemic areas; 
furthermore, antimalarials used for IPTp should be effective at promptly clearing parasitemia and 
be dosed early and often.  
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Figure legends  
Figure 1. Flowchart of study participants 
 
Figure 2. Proportion of women with placental malaria by (A) proportion of interval assessments 
with microscopic parasitemia and (B) proportion of interval assessments with any parasitemia. 
Numbers at the bottom of each bar represent the total number of patients in the category (n).  
 
Figure 3. Proportion of high-powered microscopy fields with pigment by proportion of interval 
assessments with any parasitemia among those with placental malaria. Numbers at the bottom of 
each bar represent the total number of patients in the category (n).  
 
Figure 4.  Proportion of women with placental malaria by geometric mean parasite density, 
stratified by proportion of interval assessments with any parasitemia. Numbers at the bottom of 
each bar represent the total number of patients in the category (n). 
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Table 1. Characteristics of study participants  
Study period Characteristic 
Treatment arm 
Monthly SP Monthly DP 
Enrollment  
Number of participants 311 326 
Age in years, mean (SD) 24.0 (6.0) 23.9 (5.7) 
Gestational age in weeks, mean (SD) 15.7 (2.4) 15.4 (2.3) 
Gravidity, n (%)  
1 
2 
3  
81 (26.1) 
65 (20.9) 
165 (53.1) 
72 (22.1) 
85 (26.1) 
169 (51.8) 
Before administration of first dose 
of IPTp 
Episodes of malaria, n (incidence*) 15 (1.13) 11 (0.81) 
Interval assessments**, n  591 621 
Interval assessments with microscopic parasitemia, n (%) 
Interval assessments with any parasitemia, n (%) 
301 (50.9)  
494 (83.6) 
338 (54.4) 
504 (81.1) 
After administration of first dose 
Episodes of malaria, n (incidence*) 70 (0.54) 3 (0.02) 
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of IPTp Interval assessments, n  1516 1616 
Interval assessments with microscopic parasitemia, n (%) 
Interval assessments with any parasitemia, n (%) 
45 (30.6) 
973 (64.2) 
9 (0.5) 
326 (20.2) 
Placental outcomes 
Parasites detected in placental blood by microscopy, n/N (%) 
Parasites detected in placental blood by LAMP, n/N (%) 
Parasites or pigment detected by histopathology, n/N (%) 
27/307 (8.8) 
67/301 (22.3) 
192/311 (61.7) 
1/326 (0.3) 
7/323 (2.2) 
92/326 (28.2) 
*Episodes per person-years 
**Includes enrollment visit  
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Variable Categories n 
Placental  
malaria, n (%) 
Unadjusted analysis Adjusted analysis 
RR (95% CI) p-value RR (95% CI) p-value 
Proportion of 
interval assessments 
with any parasitemia 
0-25% 142 16 (11.3) reference group reference group 
25-50% 258 95 (36.8) 3.27 (2.00-5.33) <0.001 1.95 (1.19-3.19) 0.008 
50-75% 126 76 (60.3) 5.35 (3.30-8.68) <0.001 2.31 (1.38-3.85) 0.001 
75% 111 97 (87.4) 7.76 (4.86-12.4) <0.001 2.39 (1.41-4.06) 0.001 
Geometric mean 
parasite density 
1 p/μL 221 27 (12.2) reference group reference group 
1-10 p/μL 298 146 (49.0) 4.01 (2.76-5.82) <0.001 2.61 (1.73-3.94) <0.001 
 10 p/μL 118 111 (94.1) 7.7 (5.39-11.0) <0.001 3.03 (1.94-4.74) <0.001 
Gravidity 
1 153 123 (80.4) reference group reference group 
2 150 70 (46.7) 0.59 (0.49-0.71) <0.001 0.75 (0.64-0.88) 0.001 
3 334 91 (27.3) 0.34 (0.28-0.41) <0.001 0.48 (0.40-0.58) <0.001 
IPTp regimen SP 311 192 (61.7) reference group reference group 
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Table 2. 
Factors 
associated with placental malaria
DP 326 92 (28.2) 0.46 (0.38-0.56) <0.001 0.74 (0.60-0.92) 0.007 
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Table 3. Association between the timing of parasitemia and placental malaria   
Timing of parasitemia 
Placental malaria, n/N (%) 
Total Monthly SP Monthly DP 
No parasitemia detected 0/34 (0) 0/8 (0) 0/26 (0) 
Only before the 3
rd
 trimester 62/204 (30.4) 11/40 (27.5) 51 /164 (31.1) 
Only during the 3
rd
 trimester 5/21 (23.8) 5/11 (45.5) 0/10 (0) 
Before and during the 3
rd
 trimester 217/378 (57.4) 176/252 (69.8) 41/126 (32.5) 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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